



Review

Chemokines and central nervous system disorders

William J Karpus

Department of Pathology, Northwestern University Medical School, Chicago, Illinois, USA

Chemokines and their receptors are large families of inflammatory molecules responsible for a number of biologic functions including the accumulation of leukocytes at tissue sites. Over the past 8 years, a number of studies have indicated a role for chemokines in the pathogenesis of CNS inflammatory diseases. This minireview provides a brief summary of our current knowledge of chemokines and CNS inflammatory diseases including experimental autoimmune encephalomyelitis, multiple sclerosis, virus-induced demyelinating diseases, Alzheimer's disease, and central nervous system bacterial-induced diseases. *Journal of NeuroVirology* (2001) 7, 493–500.

Keywords: chemokines; chemokine receptors; demyelinating disease; central nervous system

Chemokines and chemokine receptors

Chemokines are small molecular weight chemotactic cytokines that can be classified into four subfamilies based on the position of the amino-terminal cysteines as shown in Figure 1. The known CXC, CC, C, and CX₃C chemokines and the new systematic nomenclature are shown in Table 1 (Murphy *et al*, 2000; Zlotnik and Yoshie, 2000). The CxC chemokines can be further categorized based on the presence or absence of a glutamate-leucine-arginine (ELR) motif in the amino terminus. Those chemokines that possess the ELR motif are chemotactic for neutrophils and are angiogenic, whereas the non-ELR CxC chemokines are chemotactic for activated T cells and are angiostatic (Strieter *et al*, 1995). The CC family of chemokines are chemoattractant for a wide variety of cells types including monocytes/macrophages, T lymphocytes, basophils, eosinophils, and dendritic cells (Davatelis *et al*, 1988; Schall, 1991; Taub *et al*, 1993). The C family, lymphotactin, is chemotactic for T cells and NK cells (Hedrick *et al*, 1997) and the CX₃C chemokine contains a chemokine domain attached to a membrane-bound mucin chain that produces a soluble chemoattractant after proteolysis or mRNA processing (Bazan *et al*, 1997). This chemokine is a

chemoattractant for T cells, NK cells, and neutrophils (Murphy *et al*, 2000).

Chemokines induce a variety of downstream cellular signals through specific seven-transmembrane spanning, G protein-coupled receptors (Ward and Westwick, 1998). The most characterized biologic response is cellular chemotaxis, although other cellular outcomes such as cytokine expression, cellular differentiation, and cellular survival have been described (Ward and Westwick, 1998). As shown in Table 2, chemokine receptors can also be subdivided into four families based on the chemokine family members that are specific ligands for those particular receptors. The working hypothesis in the field of neuroimmunology has been that chemokines induce leukocyte accumulation in the central nervous system (CNS) through interaction with specific receptors on the cell surface of T cells, monocytes, and neutrophils. The induction of chemokine expression in the CNS is a complex set of events that include stimuli from infiltrating inflammatory cells as well as endogenous expression. The exact tissue-specific chemokine regulatory events are not well understood.

Experimental autoimmune encephalomyelitis

Experimental autoimmune encephalomyelitis (EAE) is a CD4⁺ T cell-mediated, CNS demyelinating disease that serves as a model for multiple sclerosis (MS). Several reports have demonstrated an association between chemokine mRNA or protein expression and appearance of clinical disease. Hulkower

Address correspondence to William J Karpus, Department of Pathology, Northwestern University Medical School, 303 E. Chicago Avenue, W127, Chicago, IL 60611, USA. E-mail: w-karpus@northwestern.edu

Received 17 July 2001; accepted 17 August 2001.

CX3C:	...CXXXC.....C.....C.....	n=1
CXC:	...CX_C.....C.....C.....	n>15
CC:	...C_C.....C.....C.....	n>25
C:C.....C.....	n=2

Figure 1 Alignment of chemokine sequences between family members.

et al (1993) were the first to demonstrate the correlation between chemokine expression and EAE in the Lewis rat model. Ransohoff *et al* (1993) described expression of chemokine mRNA in the CNS of SJL/J mice with relapsing EAE. Using semi-quantitative RT-PCR and *in situ* hybridization they demonstrated

that CXCL10 and CCL2 were expressed in the spinal cord. Additional studies of relapsing EAE demonstrated up-regulation of mRNA chemokine expression for CCL5, CCL4, CCL3, CCL1, CXCL10, CCL2, CXCL1, and CCL7 just prior to the first appearance of clinical symptoms in a mouse model of EAE and that the chemokine levels remained elevated throughout the course of the disease (Godiska *et al*, 1995). In addition to these chemokines, CCL6 expression has also been associated with EAE (Asensio *et al*, 1999).

CNS chemokine mRNA correlates with histological signs of inflammation as expression is not detected in the absence of leukocyte infiltration (Glabinski *et al*, 1995, 1998). Colocalization experiments have shown that CCL3 and CCL5 were expressed by

Table 1 Chemokine family members and systematic nomenclature

CXC chemokines ^a		CC chemokines		C chemokines		CX3C chemokines	
CXCL1 ^b	Gro α ; KC; MIP-2	CCL1	I-309; TCA-3	XCL1	Lymphotactin- α ; SCM-1 α	CX3CL1	Fractalkine; neurotactin
CXCL2	Gro β ; MIP-2 β	CCL2	MCP-1; JE	XCL2	Lymphotactin- β ; SCM-1 β		
CXCL3	Gro γ	CCL3	MIP-1 α ; LD78				
CXCL4	PF-4	CCL4	MIP-1 β				
CXCL5	ENA-78	CCL5	RANTES				
CXCL6	GCP-2	CCL6	C10; MRP-1				
CXCL7	PBP; CTAP-III; β -TG; NAP-2	CCL7	MCP-3				
CXCL8	NAP-1; GCP-1; IL-8	CCL8	MCP-2				
CXCL9	Mig	CCL9	MRP-2; MIP-1 γ				
CXCL10	IP-10; CRG-2	CCL10					
CXCL11	I-TAC; β -R1; IP9; H174	CCL11	Eotaxin				
CXCL12	SDF-1 α ; SDF-1 β ; PBSF	CCL12	MCP-5				
CXCL13	BCA-1; BLC	CCL13	MCP-4				
CXCL14	BRAK; bolekin; BMAC	CCL14	CC-1; Hcc-1; NCC-2; CCCK-1; CK β 1				
CXCL15	lungkine	CCL15	HCC-2; leukotactin; MIP-5; CC-2; NCC-3; MIP-1 δ				
CXCL16		CCL16	HCC-4; LEC; NCC-4; LMC; monotactin-1; LCC-1; ILINCK				
		CCL17	TARC				
		CCL18	DC-CK-1; PARC; MIP-4; AMAC-1; CK- β 7				
		CCL19	MIP-3 β ; ELC; exodus-3; CK β 11				
		CCL20	MIP-3 α ; LARC; exodus-1; ST38				
		CCL21	6Ckine; SLC; exodus-2; TCS4; ck β 9				
		CCL22	MDC; cd/ β ck; abcd-1				
		CCL23	MPIF-1; MIP-3; ck β 8-1				
		CCL24	MPIF-2; eotaxin-2; ck β 6				
		CCL25	TECK; ck β 15				
		CCL26	Eotaxin-3; MIP-4 α				
		CCL27	Eskine; CTACK; ILC; ALP; skinkine				
		CCL28					

^aFor the CXC, CC, C, and CX3C chemokines the systematic name is listed in the first column and some common synonyms are listed in the second column.

^bELR-containing chemokines include CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8.

Table 2 Chemokine receptors

<i>Protein</i>	<i>Cellular distribution^a</i>	<i>Ligands</i>
CXCR1	N, M, T, NK, Bs, Ms, En	CXCL8; CXCL6
CXCR2	N, M, T, NK, As, Nn, Ms, En	CXCL1; CXCL2; CXCL3; CXCL7; CXCL5; CXCL6
CXCR3	T, As	CXCL10; CXCL9; CXCL11
CXCR4	My, T, B, Ep, En, DC, Nn	CXCL12
CXCR5	B, T	CXCL13
CXCR6	T	CXCL16
CCR1	N, M, T, NK, B, Ms, As, Nn	CCL5; CCL3; CCL14; CCL8; CCL7; CCL15
CCR2	M, T, B, Bs	CCL2; CCL8; CCL7; CCL13; CCL12
CCR3	Eo, Bs, T	CCL11; CCL24; CCL26; CCL5; CCL8; CCL7; CCL13; CCL15
CCR4	T	CCL17; CCL22
CCR5	T, M, DC	CCL5; CCL3; CCL4; CCL8
CCR6	T, B, DC	CCL20
CCR7	T, B, DC	CCL19; CCL21
CCR8	M, Thymus	CCL1
CCR9	T, Thymus	CCL25
CCR10	T	CCL27
CCR11	Heart, small intestine, lung	CCL2; CCL8; CCL13; CCL19; CCL21; CCL25
XCR1	T, B, NK	XCL1; XCL2
CX3CR1	N, NK, M, T	CX3CL1

^aAbbreviations: As, astrocytes; B, B cells; Bs, basophils; DC, dendritic cells; En, endothelial cells; Eo, eosinophils; Ep, epithelial cells; M, monocytes/macrophages; Ms, mast cells; My, myeloid cells; NK, natural killer cells; Nn, neurons; T, T cells.

infiltrating leukocytes, whereas CXCL10 and CCL2 were expressed only by astrocytes (Glabinski *et al*, 1997). In addition to the association between CNS mRNA levels and tissue-specific inflammation, CNS chemokine protein levels have been associated with differential phases of relapsing disease. CCL3 and CXCL10 protein levels have been shown to be elevated in the CNS following adoptive transfer of activated neuroantigen specific T cells (Karpus *et al*, 1995; Fife *et al*, 2001) and correlate with acute disease development, whereas CCL2 levels increase with the development of the relapsing phase of disease (Kennedy *et al*, 1998). It should be emphasized that the emerging data suggests different chemokine expression patterns in different EAE models and also in different mouse strains (Karpus and Ransohoff, 1998).

The biological importance of CNS chemokine expression in EAE as been demonstrated by two approaches: *in vivo* anti-chemokine antibody treatments or chemokine knockout mice. Anti-CCL3 (Karpus *et al*, 1995) and anti-CXCL10 (Fife *et al*, 2001) treatment prevented acute clinical EAE whereas anti-CCL2 treatment was shown to prevent relapsing disease (Kennedy *et al*, 1998). In addition to the role for CCL2 in relapsing EAE, through the use of knockout mice, this chemokine has also been shown to be important for CNS monocyte accumulation during acute clinical disease (Huang *et al*, 2001). A significant finding from the *in vivo* neutralization studies is that while a wide variety of chemokines may be expressed during inflammatory autoimmune

disease, only a subset of chemokines actually plays a significant biological role in disease pathogenesis.

Using a variety of EAE models, chemokine receptor mRNA analysis has been performed to demonstrate expression in the CNS (Jiang *et al*, 1998; Charles *et al*, 1999; Matejuk *et al*, 2000; Rajan *et al*, 2000) with the general conclusion that as inflammation ensues, there is an accumulation of inflammatory cells bearing chemokine receptors. Correspondingly, a reduction in CNS inflammation results is less chemokine receptor mRNA expression. A number of recent studies using genetically deficient mice have shown that CCR1 (Rottman *et al*, 2000) and CCR2 (Fife *et al*, 2000) expression are biologically important for the development of acute EAE. In the CCR1 knockout mice, there was approximately a 50% decrease in clinical disease severity; however, the mechanism behind disease attenuation is not known. Because both T cells and monocytes have been shown to express CCR1 (Gao *et al*, 1997), it is possible that CCR1 expression by either lymphocytes or monocytes or perhaps both is required for EAE development. In the CCR2 knockout mice, there was almost a total absence of disease due to a failure of monocytes to traffic to the CNS (Fife *et al*, 2000). These two examples are in contrast to EAE induction in CCR5 knockout mice where the same level of disease severity was seen compared to wild-type control animals (Tran *et al*, 2000). An advance that has come from both the chemokine and chemokine receptor studies in EAE is development of small molecular weight antagonists to chemokine receptors. Indeed, a small molecular

weight antagonist of CCR1 has shown efficacy in the inhibition of clinical EAE (Hesseltger *et al*, 1998; Liang *et al*, 2000).

Virus-induced demyelinating disease models

A number of virus-induced CNS demyelinating disease models for MS exist and two of these, murine hepatitis virus (MHV) and Theiler's murine encephalomyelitis virus (TMEV), are well studied with respect to pathogenetic mechanisms of disease induction and progression. CXCL10, CXCL9, CCL5, CCL2, CCL7, CCL4, CXCL1 mRNA expression has been shown to correlate with viral encephalitis in the brains of MHV-infected mice (Lane *et al*, 1998; Liu *et al*, 2001). Furthermore, CXCL10, CCL5, and CCL4 mRNA expression was related to the demyelinating phase of this disease. *In vivo* neutralization experiments using the anti-chemokine treatment approach revealed that CXCL9 (Liu *et al*, 2001) and CXCL10 (Liu *et al*, 2000) were functionally important for early CNS viral clearance, and CCL5 was shown to be a pivotal chemokine in the recruitment of inflammatory cells during the demyelinating phase of disease (Lane *et al*, 2000).

Chemokine expression has also been shown to be associated with clinical disease development in TMEV-induced demyelinating disease. CXCL10, CCL5, and CCL2 mRNA expression was found in the CNS of both susceptible and resistant mouse strains following viral infection (Murray *et al*, 2000). This same study demonstrated re-expression of CXCL10, CCL5, and CCL2 in the CNS of susceptible, but not resistant, mouse strains following viral clearance and coinciding with development of demyelination. CCL2 and CCL3 protein expression in the spinal cords of the susceptible SJL mouse strain also correlated with development of clinical disease symptoms (Hoffman *et al*, 1999) with CCL2 being biologically important for clinical disease development (our unpublished observations). These examples demonstrate the correlation of chemokine presence with development of histological and clinical CNS demyelinating disease.

Multiple sclerosis

The role of chemokines in the pathogenesis of MS has not been well established. An early study demonstrated elevated CCL3 expression in the CSF of MS patients compared to control patients with other neurological diseases and the increased levels correlated with increased CSF leukocyte counts (Miyagishi *et al*, 1995). Bennetts *et al* (1997) analyzed a population of MS and control patients for a correlation between the absence of one of the CCL3 receptors, CCR5, and clinical disease presentation.

Although they found that the absence of functional CCR5 had a significant protective effect against HIV infection, it did not have a protective effect against development of MS. However, the CCR5 Δ 32 mutation has been reported to confer a lower risk of recurrent disease activity (Sellebjerg *et al*, 2000). A number of investigators have demonstrated the expression of chemokines in CNS tissue of MS patients (Hvas *et al*, 1997; McManus *et al*, 1998; Simpson *et al*, 1998; Balashov *et al*, 1999; Van *et al*, 1999; Simpson *et al*, 2000a, 2000b). Recently, the expression of chemokines in the CSF of MS patients undergoing clinical episodes of disease has been examined, and the data showed that CXCL10 and CCL5 production were elevated in MS patients compared to controls and the levels of CXCL10 correlated with increased CSF leukocyte counts (Sorensen *et al*, 1999). Because both CXCL10 and CCL5 are potent T-cell chemoattractants, it is reasonable to postulate that the elevated levels of these chemokines during active episodes of MS induced migration of T cells into the CNS. Furthermore, an increase in CXCR3⁺ and CCR5⁺ T cells in the peripheral blood of MS patients has been recently reported (Balashov *et al*, 1999). IFN- β is currently a common treatment modality for MS. A recent study has shown that *in vitro* exposure of T cells to IFN- β 1a selectively inhibited mRNA expression for CCL5 and CCL3 (Zang *et al*, 2001). Furthermore, T-cell surface expression of CCR5 was significantly reduced in MS patients treated with IFN- β , correlating with decreased T-cell transmigration toward CCL5 and CCL3 (Zang *et al*, 2001). Collectively, these results demonstrate the emerging significance of chemokine expression in the CNS during human demyelinating disease as well as the increase in chemokine receptor-bearing cells and suggest a critical role for these molecules in the pathogenesis of disease development and progression.

Alzheimer's disease

It is becoming increasingly evident that Alzheimer's disease (AD) has an inflammatory component and that chemokine expression may contribute to the development and/or the progression of disease (Xia and Hyman, 1999). Immunohistochemical analysis of human brain for CCL4, CCL3, CCL5, CCL11, and CCL7 indicated that CCL4 was predominantly expressed in a subpopulation of reactive astrocytes that were more widespread in AD than control brains, yet CCL3 was predominantly expressed in neurons and weakly in some microglia in both AD and controls (Xia *et al*, 1998). In this same study, the investigators noted that many of the CCR3⁺- or CCR5⁺-reactive microglia and CCL4⁺-reactive astrocytes were found associated with amyloid deposits. Additional evidence for chemokines in AD suggests that A β can activate both

astrocytes and oligodendrocytes to express CCL2 and CCL5 (Johnstone *et al*, 1999). Moreover, A β 1-42 has been shown to induce the *in vitro* CCL2-, CCL3-, CCL4-, and CXCL8-dependent migration of monocytes (Fiala *et al*, 1998). A β 25–35 was also shown to induce CCL3 and CXCL10 expression by cultured human monocytes and mouse microglial cells (Meda *et al*, 1999). Although these studies do not explicitly demonstrate a causal role for chemokines and pathogenesis, they are the first steps toward understanding the role of chemokines and inflammation in AD.

CNS bacterial infections

The role of chemokines in control of CNS bacterial infections is also not well understood. However, there has been significant progress toward understanding the functions of these molecules in both experimental models and in patients. In experimental bacterial meningitis induced by *Listeria monocytogenes*, both CXC and CC chemokines namely CCL3, CCL4, and CXCL1 are produced intrathecally by meningeal macrophages and leukocytes that infiltrate into the CNS. In comparison, patients with bacterial meningitis demonstrate CXCL8, CXCL1, CCL2, CCL3, and CCL4 expression in the CSF (Lahrtz *et al*, 1998). In experimental CNS infections using *Haemophilus influenzae* type b, mRNA for CXCL1, CCL3, CCL2, and CCL5 was detected in the brain of neonatal rats (Diab *et al*, 1999). *In vivo* neutralization of CXCL1 or CCL3 resulted in a reduction of neutrophil accumulation, whereas anti-CCL2 treatment resulted in reduction of monocyte accumulation in the CNS (Diab *et al*, 1999). The study of a bacterial-induced brain abscess model has increased the understanding of chemokine function in CNS infections. When mouse brains were infected with *Staphylococcus aureus*, a number of chemokines were expressed locally. These included CCL3, CCL4, CXCL1, CCL2, and CCL1 (Kielian *et al*, 2001). Control of bacterial clearance and disease development appeared to be a function of CXCL1 expression as mice without CXCR2 expression failed to clear the infection because of reduced neutrophil accumulation (Kielian *et al*, 2001). These examples point to the requirement of CXC chemokines for the control of CNS bacterial infections and the subsequent development of bystander tissue destruction that results in CNS inflammatory disease.

HIV-associated dementia

CNS dysfunction has been described in HIV-infected individuals and most likely results from viral infection of cells through the use of chemokine receptors as coreceptors (reviewed in (Kaul *et al*, 2001). Chemokine receptors, most notably CCR5, CXCR4, and Cx3CR1 have been described as coreceptors for

HIV and a number of studies have shown chemokine receptor expression on neurons (Horuk *et al*, 1997), astrocytes (Tanabe *et al*, 1997; Cota *et al*, 2000), endothelia (Molino *et al*, 2000), and microglia (He *et al*, 1997; Ghorpade *et al*, 1998). Neuronal damage following HIV infection could result from either an infiltration of inflammatory leukocytes (Persidsky *et al*, 1999) resulting in cellular death, direct neuronal apoptosis (Zheng *et al*, 1999), or indirect stimulation of glia-derived neurotoxic factors (Kaul and Lipton, 1999). The role of chemokines in HIV-associated dementia (HAD) is not well understood. For instance, in patients with HAD, the levels of CCL3, CCL4, and CCL5 in the CSF positively correlate with dementia although low levels of CCL3 may be neuroprotective (Letendre *et al*, 1999). Moreover, CCL3, CCL4, and CCL5 have been shown to protect neurons from gp120-induced cell death (Meucci *et al*, 1998; Kaul and Lipton, 1999). It is clear that chemokines and chemokine receptors are involved in the pathogenesis of HAD although the mechanisms are not clearly understood.

Summary

Chemokines and their receptors are a growing family of inflammatory molecules that are associated with many tissue-specific inflammatory events and the CNS is no exception. One current view of chemokines is to regulate the migration and/or accumulation of leukocytes at a particular tissue site for the general function of infection clearance and tissue repair. However, aberrant accumulation of leukocytes, including antigen-specific T cells and monocytes, can induce pathology and result in tissue-specific autoimmune and/or inflammatory disease. Our greatest understanding of the role of chemokines in CNS disorders comes from the EAE model where the temporal and spatial chemokine expression patterns appear to regulate mononuclear cell accumulation and subsequent disease development (Karpus and Ransohoff, 1998). In the case of autoimmune disease or bystander inflammatory disease, it would be beneficial to limit the biological effect of chemokine expression to limit the extent of self-tissue damage.

To this end, small molecular weight chemokine receptor antagonists have been developed and are being evaluated for efficacy in disease models as well as human disease (Ransohoff and Bacon, 2000). However, in the case of CNS bacterial infections it would be deleterious to generally inhibit the function of chemokines; as a subset, these molecules are required for the accumulation of neutrophils and the resulting clearance of infection. In this particular instance, it might be beneficial to use selective antagonists for monocytes and T cells to inhibit self tissue destruction while allowing accumulation of neutrophils. Nevertheless, understanding the role

of this superfamily of inflammatory molecules in diseases of the CNS will shed light on specific pathogenetic mechanisms as well as provide targets for therapeutic intervention.

References

- Asensio VC, Lassmann S, Pagenstecher A, Steffensen SC, Henriksen SJ, Campbell IL (1999). C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. *Am J Pathol* **154**: 1181–1191.
- Balashov KE, Rottman JB, Weiner HL, Hancock WW (1999). CCR5⁺ and CXCR3⁺ T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. *Proc Natl Acad Sci USA* **96**: 6873–6878.
- Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997). A new class of membrane-bound chemokine with a CX3C motif. *Nature* **385**: 640–644.
- Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ (1997). The CCR5 deletion mutation fails to protect against multiple sclerosis. *Hum Immunol* **58**: 52–59.
- Charles PC, Weber KS, Cipriani B, Brosnan CF (1999). Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. *J Neuroimmunol* **100**: 64–73.
- Cota M, Kleinschmidt A, Ceccherini-Silberstein F, Aloisi F, Mengozzi M, Mantovani A, Brack-Werner R, Poli G (2000). Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. *J Neuro Virol* **6**: 75–83.
- Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Gallegos C, Coit D, Merryweather J, Cerami A (1988). Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokine properties. *J Exp Med* **167**: 1939–1944.
- Diab A, Abdalla H, Li HL, Shi FD, Zhu J, Hojberg B, Lindquist L, Wretling B, Bakhiet M, Link H (1999). Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. *Infect Immun* **67**: 2590–2601.
- Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE (1998). Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. *Mol Med* **4**: 480–489.
- Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ (2000). CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. *J Exp Med* **192**: 899–906.
- Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, Karpus WJ (2001). CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4⁺ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. *J Immunol* **166**: 7617–7624.
- Gao JL, Wynn TA, Chang Y, Lee EJ, Broxmeyer HE, Cooper S, Tiffany HL, Westphal H, Kwon-Chung J, Murphy PM (1997). Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. *J Exp Med* **185**: 1959–1968.
- Ghospade A, Xia MQ, Hyman BT, Persidsky Y, Nukuna A, Bock P, Che M, Limoges J, Gendelman HE, Mackay CR (1998). Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. *J Virol* **72**: 3351–3361.
- Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM (1997). Synchronous synthesis of α - and β -chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. *Am J Pathol* **150**: 617–630.
- Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM (1995). Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. *Brain Behav Immun* **9**: 315–330.
- Glabinski AR, Tuohy VK, Ransohoff RM (1998). Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. *Neuroimmunomodulation* **5**: 166–171.
- Godiska R, Chantry D, Dietsch GN, Gray PW (1995). Chemokine expression in murine experimental allergic encephalomyelitis. *J Neuroimmunol* **58**: 167–176.
- He JL, Chen YZ, Farzan M, Choe HY, Ohagen A, Gartner S, Busciglio J, Yang XY, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D (1997). CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature* **385**: 645–649.
- Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu YM, Menon S, Abrams J, Handel T, Zlotnik A (1997). Lymphotactin is produced by NK cells and attracts both NK cells and T cells *in vivo*. *J Immunol* **158**: 1533–1540.
- Hesselgesser J, Ng HP, Liang M, Zheng W, May K, Bauman JG, Monahan S, Islam I, Wei GP, Ghannam A, Taub DD, Rosser M, Snider RM, Morrissey MM, Perez HD, Horuk R (1998). Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. *J Biol Chem* **273**: 15687–15692.
- Hoffman LM, Fife BT, Begolka WS, Miller SD, Karpus WJ (1999). Central nervous system chemokine expression during Theiler's virus-induced demyelinating disease. *J Neuro Virol* **5**: 635–642.
- Horuk R, Martin AW, Wang Z, Schweitzer L, Gerassimides A, Guo H, Lu Z, Hesselgesser J, Perez HD, Kim J, Parker J, Hadley TJ, Peiper SC (1997). Expression of chemokine receptors by subsets of neurons in the central nervous system. *J Immunol* **158**: 2882–2890.

Acknowledgements

The author's work is supported by NIH grants AI35934, NS34510, and NMSS grant RG-3056-A-2.

- Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM (2001). Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. *J Exp Med* **193**: 713–726.
- Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, Rapoport DA, Berman JW (1993). Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. *J Immunol* **150**: 2525–2533.
- Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR, Bernard CCA (1997). Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions. *Scand J Immunol* **46**: 195–203.
- Jiang Y, Salafranca MN, Adhikari S, Xia Y, Feng L, Sonntag MK, deFiebre CM, Pennell NA, Streit WJ, Harrison JK (1998). Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. *J Neuroimmunol* **86**: 1–12.
- Johnstone M, Gearing AJ, Miller KM (1999). A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. *J Neuroimmunol* **93**: 182–193.
- Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD (1995). An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. *J Immunol* **155**: 5003–5010.
- Karpus WJ, Ransohoff RM (1998). Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. *J Immunol* **161**: 2667–2671.
- Kaul M, Garden GA, Lipton SA (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature* **410**: 988–994.
- Kaul M, Lipton SA (1999). Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. *Proc Natl Acad Sci USA* **96**: 8212–8216.
- Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ (1998). Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 α and monocyte chemoattractant protein-1. *J Neuroimmunol* **92**: 98–108.
- Kielian T, Barry B, Hickey WF (2001). CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses. *J Immunol* **166**: 4634–4643.
- Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A (1998). Chemokines and chemotaxis of leukocytes in infectious meningitis. *J Neuroimmunol* **85**: 33–43.
- Lane TE, Asensio VC, Yu N, Paoletti AD, Campbell IL, Buchmeier MJ (1998). Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. *J Immunol* **160**: 970–978.
- Lane TE, Liu MT, Chen BP, Asensio VC, Samawi RM, Paoletti AD, Campbell IL, Kunkel SL, Fox HS, Buchmeier MJ (2000). A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. *J Virol* **74**: 1415–1424.
- Letendre SL, Lanier ER, McCutchan JA (1999). Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. *J Infect Dis* **180**: 310–319.
- Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei GP, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD (2000). Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. *J Biol Chem* **275**: 19000–19008.
- Liu MT, Armstrong D, Hamilton TA, Lane TE (2001). Expression of Mig (monokine induced by interferon-gamma) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system. *J Immunol* **166**: 1790–1795.
- Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA, Lane TE (2000). The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. *J Immunol* **165**: 2327–2330.
- Matejuk A, Vandenbark AA, Burrows GG, Bebo BF Jr, Offner H (2000). Reduced chemokine and chemokine receptor expression in spinal cords of TCR BV8S2 transgenic mice protected against experimental autoimmune encephalomyelitis with BV8S2 protein. *J Immunol* **164**: 3924–3931.
- McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF (1998). MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and *in situ* hybridization study. *J Neuroimmunol* **86**: 20–29.
- Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F (1999). Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25–35]. *J Neuroimmunol* **93**: 45–52.
- Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ (1998). Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. *Proc Natl Acad Sci USA* **95**: 14500–14505.
- Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K (1995). Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. *J Neurol Sci* **129**: 223–227.
- Molino M, Woolkalis MJ, Prevost N, Pratico D, Barnathan ES, Taraboletti G, Haggarty BS, Hesselgesser J, Horuk R, Hoxie JA, Brass LF (2000). CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. *Biochim Biophys Acta* **1500**: 227–240.
- Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev* **52**: 145–176.
- Murray PD, Krivacic K, Chernosky A, Wei T, Ransohoff RM, Rodriguez M (2000). Biphasic and regionally-restricted chemokine expression in the central nervous system in the Theiler's virus model of multiple sclerosis. *J Neuro Virol* **6 Suppl 1**: S44–S52.

- Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE (1999). Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. *Am J Pathol* **155**: 1599–1611.
- Rajan AJ, Asensio VC, Campbell IL, Brosnan CF (2000). Experimental autoimmune encephalomyelitis on the SJL mouse: effect of gamma delta T cell depletion on chemokine and chemokine receptor expression in the central nervous system. *J Immunol* **164**: 2120–2130.
- Ransohoff RM, Bacon KB (2000). Chemokine receptor antagonism as a new therapy for multiple sclerosis. *Expert Opin Investig Drugs* **9**: 1079–1097.
- Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, Estes ML, Thomas DM, Tuohy VK (1993). Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. *FASEB J* **7**: 592–600.
- Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW (2000). Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. *Eur J Immunol* **30**: 2372–2377.
- Schall TJ (1991). Biology of the RANTES/SIS cytokine family. *Cytokine* **3**: 165–183.
- Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P (2000). CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. *J Neuroimmunol* **102**: 98–106.
- Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroffe MN (2000a). Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. *J Neuroimmunol* **108**: 192–200.
- Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN (1998). Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. *J Neuroimmunol* **84**: 238–249.
- Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN (2000b). Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. *Neuropathol Appl Neurobiol* **26**: 133–142.
- Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. *J Clin Invest* **103**: 807–815.
- Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan SY, Roczniak S, Shanafelt AB (1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J Biol Chem* **270**: 27348–27357.
- Tanabe S, Heesen M, Yoshizawa I, Berman MA, Luo Y, Bleul CC, Springer TA, Okuda K, Gerard N, Dorf ME (1997). Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. *J Immunol* **159**: 905–911.
- Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ (1993). Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 α and MIP-1 β . *Science* **260**: 355–358.
- Tran EH, Kuziel WA, Owens T (2000). Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1 α or its CCR5 receptor. *Eur J Immunol* **30**: 1410–1415.
- Van DV, Tekstra J, Beelen RH, Tensen CP, Van DV, De GC (1999). Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. *Am J Pathol* **154**: 45–51.
- Ward SG, Westwick J (1998). Chemokines: understanding their role in T-lymphocyte biology. *Biochem J* **333**: 457–470.
- Xia MQ, Hyman BT (1999). Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. *J NeuroVirol* **5**: 32–41.
- Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT (1998). Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. *Am J Pathol* **153**: 31–37.
- Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ (2001). Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1 α by interferon-beta. *J Neuroimmunol* **112**: 174–180.
- Zheng J, Thylin MR, Ghorpade A, Xiong H, Persidsky Y, Cotter R, Niemann D, Che M, Zeng YC, Gelbard HA, Shepard RB, Swartz JM, Gendelman HE (1999). Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. *J Neuroimmunol* **98**: 185–200.
- Zlotnik A, Yoshie O (2000). Chemokines: a new classification system and their role in immunity. *Immunity* **12**: 121–127.